The 12 possible monomethylbenz[a]anthracenes (MBAs) were examined for their tumor-initiating activity in the classical two-stage initiation-promotion experiment. Based on the average number of tumors/mouse, 7-MBA was the most tumorigenic compound of the series causing 4.9 papillomas/mouse at an initiating dose of 400 nmol/mouse. At this same dose level 8-MBA and 12-MBA were equally potent causing 1.0 papillomas/mouse. 6- an 9-MBAs caused -0.6 papillomas/mouse at this dose level. These data are in general agreement with previous experiments using other model systems. Of interest is the low tumorigenicity of the 1-, 2-, 3-and 4-MBAs which has been cited in support of the bay region theory of polycyclic aromatic hydrocarbon carcinogenesis. The tumor-initiating ability of anthracene and 9,10-dimethylanthracene was also examined. Neither of these compounds possessed tumor-initiating activity.
The tumor-initiating activity of the 3,4-dihydrodiols (diols) as well as other metabolites of 8-methylbenz[a]anthracene (8-MBA) and 8-hydroxymethylbenz[a]anthracene (8-OHMBA) were examined in the classical 2-stage initiation-promotion model on mouse skin. The 3,4-diol of 8-MBA caused 2.2 times as many papillomas/mouse as did 8-MBA. The 3,4-diol of 8-OHMBA was not more tumorigenic than either 8-MBA or 8-OHMBA. None of the other diols tested, including the 5,6- and 8,9-diol of 8-MBA and the 5,6 and 10,11-diol of 8-OHMBA were remarkably tumorigenic. These data indicate that the 3,4-diol of 8-MBA is a good candidate as a proximate carcinogen of 8-MBA and further suggest that the bay region 3,4-diol-1,2-epoxide is a likely ultimate carcinogen of this compound on mouse skin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.